+154.8%
PLD vs MRNA
+561.6%
-406.8%
-43.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.7% | -2.2% | +1.5% | -0.6% |
| 7D | -2.4% | +5.5% | -7.9% | -2.6% |
| 30D | -2.4% | +158.7% | -161.2% | -9.0% |
| 3M | -3.8% | +182.1% | -185.9% | -11.2% |
| 6M | 0.0% | +151.8% | -151.8% | -7.2% |
| YTD | +9.2% | +393.6% | -384.3% | -3.4% |
| 1Y | +25.9% | +499.5% | -473.6% | +9.5% |
| 3Y | +21.3% | +29.3% | -8.0% | +12.5% |
| 5Y | +14.1% | -65.1% | +79.2% | +7.4% |
| All | +154.8% | +561.6% | -406.8% | +138.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling